MedTrace Logo

Profound Dermal and SubQ Cartridges for the Treatment of Cellulite

NCT03078647 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2019-06-25

Study results available
· View outcomes & findings →

Summary

Clinical Study to Evaluate the Performance of the Profound System for the Treatment of Cellulite.

Conditions

  • Cellulite

Interventions

DEVICE

Profound

The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.

Sponsors & Collaborators

  • Syneron Medical

    lead INDUSTRY

Principal Investigators

  • Girish Munavalli, MD · Laser & Vein Specialists of the Carolinas

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-13
Primary Completion
2018-11-02
Completion
2019-01-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03078647 on ClinicalTrials.gov